Teva Reports Baseline Patient Characteristics From TOP MS Study - Quick Facts

Teva Neuroscience Inc., a subsidiary of Teva Pharmaceutical Industries Ltd. (TEVA: News ), Sunday announced baseline patient characteristics from the fully enrolled Therapy Optimization in Multiple Sclerosis study.Therapy Optimization in Multiple Sclerosis or TOP MS represents the largest prospective Phase IV study conducted in multiple sclerosis. Multiple sclerosis is a chronic, often disabling disease that attacks the central nervous system. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision.Of the 2,901 participants who have completed surveys, 80.4 percent were female, while 89.9 percent were Caucasian and 5.8 percent were African-American. Mean age of the participants was 49 years old.A total of 36.1 percent reported using a prior disease-modifying therapy or DMT with a mean number of 1.4 therapies.About 67.1 percent of the participants reported numbness and tingling as the first symptoms of multiple sclerosis, while 45.6 percent reported loss of vision. Fatigue was reported as one of the first symptoms by 44.1 percent, while 40.5 percent had impaired coordination or balance.